NICE TA187 Infliximab and adalimumab for P1 - BNSSG NICE Commissioning In progress - Gastroenterology Tom Creed (Cons) the treatment of Crohn’s disease College priority ID3122 P2 - Clinical Effectiveness Group SpyGlass Peroral Direct Visualisation Hepatology Jim Portal (Cons) priority Introduction of a new Not initiated Cholangioscopy interventional procedure GI bleeding Hepatology Anne McCune (Cons) P3 - NICE Guidance Not initiated
NICE TA187 Infliximab and adalimumab for the treatment of Crohn’s disease Gastroenterology Tom Creed (Cons) P1 - BNSSG NICE Commissioning College priority In progress - ID3122 SpyGlass Peroral Direct Visualisation Cholangioscopy Hepatology Jim Portal (Cons) P2 - Clinical Effectiveness Group priority Introduction of a new interventional procedure Not initiated GI bleeding Hepatology Anne McCune (Cons) P3 - NICE Guidance Not initiated
uhbristol_ca_annual_report_2012-13_-_final_for_qoc.docx